Gold Nanoparticles Revolutionize Prostate Cancer Treatment: Integrating Targeted Drug Delivery, Photothermal Therapy, and Multimodal Imaging

August 23, 2026

MDPI Switzerland

Overview

Gold nanoparticles (AuNPs) are emerging as promising multifunctional nanoplatforms for prostate cancer treatment, leveraging their tunable size, shape, surface plasmon resonance (SPR) properties, and high surface-to-volume ratio. AuNPs facilitate targeted drug delivery, enhanced drug loading, and improved bioavailability. Notably, nanoparticles sized 40-60 nm show optimal cellular uptake in prostate cancer cells, enabling selective drug concentration. AuNPs also integrate photothermal therapy (PTT), radiosensitization, and multimodal imaging, contributing to personalized, high-precision therapies.

In Depth

Key Findings

Gold nanoparticles (AuNPs) have emerged as highly promising multifunctional nanoplatforms for the treatment of prostate cancer, owing to their unique physicochemical properties. AuNPs can be precisely tuned in terms of size, shape, surface plasmon resonance (SPR) characteristics, and high surface-to-volume ratio, contributing to targeted drug delivery, enhanced drug loading capacity, and improved drug bioavailability in vivo. Specifically, AuNPs with diameters of approximately 40-60 nm have been reported to exhibit the most efficient intracellular uptake in prostate cancer cells, which is crucial for maximizing therapeutic efficacy.

Technical / Clinical Details

The advantages of AuNPs stem primarily from their excellent biocompatibility, ease of surface chemical modification, and distinct optical properties. AuNP surfaces can be functionalized with various targeting ligands, such as folic acid, antibodies, or peptides, enabling ‘active targeting’ to specifically deliver drugs to prostate cancer cells. Ligand-modified AuNPs bind to overexpressed receptors on cancer cell surfaces and are efficiently internalized via receptor-mediated endocytosis. Once inside the cells, AuNPs not only release therapeutic agents within the tumor but can also act as photothermal therapy (PTT) agents, destroying cancer cells with heat when exposed to near-infrared laser light. Furthermore, AuNPs show promise for radiosensitization in combination with radiotherapy and as contrast agents in multimodal imaging (CT, MRI, photoacoustic imaging), contributing to the realization of theranostic approaches that integrate diagnosis and therapy.

Background & Context

Prostate cancer is one of the most common cancers among men, demanding early detection and effective treatment strategies. However, existing treatments for advanced prostate cancer often come with systemic side effects and a risk of recurrence. Consequently, there is an urgent need for the development of less invasive and highly target-specific therapies. Nanomedicine, with its precise drug delivery capabilities and multifunctionality, is recognized as a promising approach to transform the paradigm of cancer treatment, and AuNPs are among the most actively researched materials in this domain.

Strategic Significance & Outlook

The application of gold nanoparticles in prostate cancer treatment is currently progressing from preclinical to early clinical stages. Future efforts will focus on evaluating the long-term in vivo safety, biodegradability, and scalability for large-scale production of AuNPs. If this technology reaches clinical application, it has the potential to offer personalized and precise treatment options for prostate cancer patients with superior efficacy and fewer side effects than conventional therapies. In the long term, the application of AuNPs as nanocarriers for various types of cancer and other diseases will also be explored.

Source: https://www.mdpi.com/1424-8247/19/8/1273

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.